Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...

The PERSEUS trial was a global, double-blind, randomized Phase 3 study comparing tolebrutinib to placebo in PPMS patients.

Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...

Kyverna Therapeutics announced positive topline data from a phase II trial of mivocabtagene autoleucel, a chimeric antigen ...

Sanofi has agreed $1.7bn and $1.04bn licensing deals with Dren Bio and ADEL, respectively. Following the disappointment of a ...

Tolebrutinib failed to meet the primary endpoint in the phase 3 PERSEUS study involving patients with primary progressive multiple sclerosis.

The ECB meets on Thursday and is widely expected to hold its key rate at 2% for a fourth straight meeting. Traders will be ...

Sanofi’s PERSEUS phase 3 study of tolebrutinib in primary progressive multiple sclerosis fails to meet primary endpoint: Paris Tuesday, December 16, 2025, 11:00 Hrs [IST] Sanofi ...

Sanofi SA reported more hitches in the development of Bruton’s tyrosine kinase inhibitor tolebrutinib, saying the phase III Perseus study failed to meet its primary endpoint in primary progressive ...

Sanofi is back with its second pact of the day, this time announcing a licensing deal for a South Korean biotech’s antibody ...

A multiple sclerosis drug at the center of a multibillion-dollar Bay Area acquisition has hit more roadblocks.

Sanofi sees continued growth and strong financials despite a pipeline setback. Click for this updated look at SNY stock ...